CRSP stock has fallen 17% over the last twenty-one trading days, after a rise in bond yields, along with rising inflationary concerns, led to a drop in growth stocks, including CRSP, NTLA and EDIT, among others. There has been no company-specific announcement that may warrant a decline in CRSP stock.
What's happening with CRISPR Therapeutics stock?
CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has plunged by 14% over the last 10 trading days, and it is down 10% over the last 5 trading days.
Is CRSP stock poised to decline further?
While the CRSP stock saw a 14% decline over the last 10 days, it has seen a whopping 3x move over the last year. Now, is CRSP stock poised to decline further? We don’t think so. We believe that the gene editing companies, including CRISPR, will likely see gains in the near term, driven by increased investor expectations from the pipeline.
Is CRISPR Therapeutics'Kymriah safe?
Most importantly, CRISPR Therapeutics said there were no grade 3 or higher cytokine release syndrome events in the trial. This serious and potentially life-threatening safety issue has plagued autologous CAR-T therapies such as Novartis ' Kymriah and Gilead Sciences ' Yescarta.
Is Maxx chatsko stock a buy for CRISPR Therapeutics?
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Why is CRISPR stock down?
CRISPR Therapeutics (CRSP 5.41%) stock sank by 15.9% in January, according to data from S&P Global Market Intelligence, amid a surge of bearish momentum impacting the broader market. An assortment of risk factors last month led investors to sell stocks lower.
Is CRISPR stock worth buying?
Yes, CRISPR Therapeutics boasts explosive upside potential, but it also comes with a decent amount of risk, more so than many investors can handle.
What is happening with CRISPR?
New CRISPR-Combo Boosts Genome Editing Power in Plants May 23, 2022 — Scientists have developed CRISPR-Combo, a method to edit multiple genes in plants while simultaneously changing the expression of other genes. This new tool will enable genetic engineering ...
Will CRISPR Therapeutics stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 113.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +116.56% increase from the last price of 52.41.
Is CRISPR a good investment 2021?
CRISPR Therapeutics is currently a very high upside company from its current $5.19B market cap. Risk averse or short-term investors, however, should avoid CRISPR Therapeutics because the stock is likely to be very volatile with lots of potential downside.
What will CRSP stock be worth in 2025?
CRISPR Technologies: 191,416% implied sales growth by 2025 CRISPR Therapeutics (CRSP 8.29%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025.
Who owns CRISPR stock?
Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedBlackRock Fund Advisors2.53%1,962,052Loomis, Sayles & Co. LP1.67%1,290,905Fidelity Management & Research Co...1.63%1,261,622The Vanguard Group, Inc.1.51%1,170,3366 more rows
What is the best genomic stock to buy?
Illumina. Illumina is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment. ... Pacific Biosciences of California. ... Exact Sciences. ... Invitae. ... Fulgent Genetics. ... Intellia Therapeutics. ... CRISPR Therapeutics.
Who is CEO of CRISPR?
Dr. Samarth KulkarniDr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies.
What is the best CRISPR stock?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row•Jan 7, 2022
Is CRSP undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of CRSP, demonstrate its potential to underperform the market.
What is the best CRISPR stock to buy?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row•Jan 7, 2022
Is CRSP stock a good long term investment?
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2021. The Zacks Consensus Estimate has increased $3.67 to $4.81. CRSP boasts an average earnings surprise of 21.6%. Additionally, CRSP's earnings are expected to grow 190.9% for the current fiscal year.
Should I buy CRISPR stock Zacks?
Zacks' proprietary data indicates that CRISPR Therapeutics AG is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CRSP shares relative to the market in the next few months.
What is CRSP worth?
Corsair Gaming net worth as of May 26, 2022 is $1.44B. Compare CRSR With Other Stocks.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies.
So what
While CRISPR Therapeutics framed the results as positive, the tested efficacy levels for CTX110 appear to have fallen short of the market's expectations. The trial found that CTX110 had a 58% overall response rate and a 38% complete response rate in large B-cell lymphoma. Analysts were mixed on the performance and implications.
Now what
CRISPR stock has regained some ground early in November's trading. The company's share price is up roughly 6% in the month so far.
Key Points
Following some stellar gains, investors took a more cautious approach to CRISPR Therapeutics stock in 2021.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
So what
CRISPR Therapeutics' drug pipeline revolves around chimeric antigen receptor T-cells (CAR-T) that can be used to target malignant tumors.
Now what
CRISPR stock has continued to lose ground early in 2022's trading. The company's share price is down roughly 11% in January's trading so far.
What happened
Shares of the gene-editing titan CRISPR Therapeutics ( CRSP 4.50% ) are seemingly in for a bad day. The biotech's stock dropped by nearly 10% in premarket trading today in response to an early look at phase 1 trial results for its blood cancer candidate CTX110.
NASDAQ: CRSP
The biotech's stock has rebounded to some degree since the official start of today's trading session. But the company's shares are still down by a noteworthy 7% as of 9:58 a.m. EDT Wednesday morning.
So what
CRISPR Therapeutics, for its part, said that these initial results were encouraging enough to potentially advance the therapy into a registrational trial. That trial could kick off as soon as the first quarter of next year, according to the company's press release.
Now what
So, at this way too early juncture, CRISPR Therapeutics' off-the-shelf CAR-T therapy looks to be safer than the approved treatments from Novartis and Gilead Sciences, but it might be less effective overall. At least that seems to be the message some investors are walking away with today, given the biotech stock 's poor reaction to this news.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What happened
Shares of CRISPR Therapeutics ( CRSP -4.33% ) are falling today, down by 9.7% as of 1:53 p.m. EST, after the company announced the pricing of a public stock offering. The gene-editing pioneer said it will offer up to 4.89 million shares at $64.50 apiece, which would generate gross proceeds of up to $315 million.
So what
CRISPR Therapeutics is exploring many applications for its gene-editing technology. For instance, CTX001 attempts to engineer cells in bone marrow such that the resulting red blood cells generated can function properly and relieve individuals suffering from sickle cell disease or beta thalassemia.
Now what
Even after taking today's tumble into account, shares of CRISPR Therapeutics are up 112% since the beginning of the year. Given a pipeline that is (or soon will be) buzzing with activity, it makes sense for the pharma stock to bolster its cash position.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
